
Please try another search
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. Its lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus for wound healing indications. Cambium Bio Limited is based in Paddington, Australia.
Name | Age | Since | Title |
---|---|---|---|
Doyle Stulting | - | - | Member of Advisory Board |
Yu-Hung Tseng | - | 2024 | Non-Executive Director |
Terence Allen Walts | 77 | - | Non-Executive Director |
Louis Tong | - | 2024 | Member of Advisory Board |
Li-Chien Chiu | - | 2025 | Non-Executive Director |
Chandra Bala | - | 2024 | Non-Executive Director |
Edmund Kemp Waller | - | 2024 | Chairman & Chief Scientific Officer |
Chi-Tai Chang | - | 2024 | Non-Executive Director |
Denese C. Marks | - | 2025 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review